Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,891 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Patients Clear all
Completed No phase listed Observational Accepts healthy volunteers

Carbon-11 Labeled Sarcosine in Prostate Cancer

NCT02462447
View directory record Official record
Conditions
Prostate Cancer
Interventions
11C-sarcosine, 11C-choline
Drug
Lead sponsor
University of Michigan
Other
Eligibility
40 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 30, 2026, 10:15 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

NCT00050687
View directory record Official record
Conditions
Prostatic Neoplasms, Multiple Myeloma, Bladder Neoplasms, Lymphoma
Interventions
Gallium maltolate
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
5
States / cities
Springdale, Arkansas • Greenbrae, California • Palo Alto, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2011 · Synced Oct 30, 2026, 10:15 PM EDT
Completed Not applicable Interventional

Tangerine or Red Tomato Juice in Treating Patients With Prostate Cancer Undergoing Surgery

NCT02144649
View directory record Official record
Conditions
Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
dietary intervention (tangerine tomato juice), dietary intervention (red tomato juice), questionnaire administration, Correlative studies
Dietary Supplement · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Columbus, Ohio • Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 30, 2026, 10:15 PM EDT
Completed Phase 2 Interventional

Doxercalciferol Before Surgery in Treating Localized Prostate Cancer

NCT00022412
View directory record Official record
Conditions
Prostate Cancer
Interventions
doxercalciferol, conventional surgery
Dietary Supplement · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 120 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
6
States / cities
Iowa City, Iowa • Rochester, New York • Madison, Wisconsin + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 30, 2026, 10:15 PM EDT
Completed Phase 1 Interventional

Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors

NCT02285101
View directory record Official record
Conditions
Melanoma, Prostate Adenocarcinoma
Interventions
PEG-BCT-100
Biological
Lead sponsor
Bio-Cancer Treatment International Limited
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
San Diego, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 30, 2026, 10:15 PM EDT
Completed Phase 1 Interventional

Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer

NCT00003439
View directory record Official record
Conditions
Cancer
Interventions
recombinant interleukin-12
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 30, 2026, 10:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Duke Urology Database and Specimen Bank

NCT00978991
View directory record Official record
Conditions
Prostate Cancer, Bladder Cancer, Erectile Dysfunction, Incontinence
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
87,820 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1988 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 30, 2026, 10:15 PM EDT
Terminated Phase 2 Interventional

Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer

NCT00521274
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
MVA 5T4, Docetaxel
Biological · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 30, 2026, 10:15 PM EDT
Completed Phase 1 Interventional

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

NCT00868595
View directory record Official record
Conditions
Castrate Resistant Prostate Cancer (CRPC)
Interventions
BPX-101, AP1903
Biological · Drug
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 30, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00049257
View directory record Official record
Conditions
Prostate Cancer
Interventions
carboplatin, paclitaxel
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 30, 2026, 10:15 PM EDT
Terminated Not applicable Interventional

A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer

NCT01940237
View directory record Official record
Conditions
Depression, Pancreatic Cancer, Lung Cancer, Colon Cancer, Prostate Cancer
Interventions
Psychotherapy
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 30, 2026, 10:15 PM EDT
Completed Phase 1Phase 2 Interventional

Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate

NCT01868386
View directory record Official record
Conditions
Prostate Cancer
Interventions
Hypofractionated therapy
Radiation
Lead sponsor
Timothy Showalter, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
3
States / cities
Charlottesville, Virginia • Norton, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 30, 2026, 10:15 PM EDT
Not listed Phase 1 Interventional

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00090727
View directory record Official record
Conditions
Solid Malignancies, Non-Hodgkin's Lymphoma
Interventions
AQ4N
Drug
Lead sponsor
Novacea
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
The Bronx, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2006 · Synced Oct 30, 2026, 10:15 PM EDT
Recruiting Phase 3 Interventional

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803
View directory record Official record
Conditions
Prostate Cancer
Interventions
Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 10:15 PM EDT
Recruiting Phase 2 Interventional

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

NCT06738303
View directory record Official record
Conditions
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
Cabazitaxel and carboplatin, Lu-PSMA-617
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 10:15 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

NCT04126070
View directory record Official record
Conditions
Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma
Interventions
Androgen Deprivation Therapy, Nivolumab, Docetaxel
Drug
Lead sponsor
Xiao X. Wei, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
La Jolla, California • Tampa, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 10:15 PM EDT
Not listed Phase 1Phase 2 Interventional

Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

NCT02935205
View directory record Official record
Conditions
Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Enzalutamide, Indomethacin
Drug
Lead sponsor
Mamta Parikh
Other
Eligibility
19 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 30, 2026, 10:15 PM EDT
Active, not recruiting Early Phase 1 Interventional

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

NCT04147494
View directory record Official record
Conditions
Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Kidney Carcinoma, Lung Carcinoma, Ovarian Carcinoma, Pancreatic Carcinoma, Solid Neoplasm, Uterine Corpus Cancer
Interventions
Computed Tomography, Gallium Ga 68 FAPi-46, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography, 18F-FDG
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 30, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

NCT01251861
View directory record Official record
Conditions
Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7
Interventions
Akt Inhibitor MK2206, Bicalutamide, Clinical Observation, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
192
States / cities
Palo Alto, California • Aurora, Colorado • Boulder, Colorado + 139 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 30, 2026, 10:15 PM EDT
Completed Not applicable Interventional

An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients

NCT00235794
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
temsirolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 30, 2026, 10:15 PM EDT
Suspended Phase 1Phase 2 Interventional

Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical

NCT06643494
View directory record Official record
Conditions
Prostate Cancer
Interventions
N-111, Placebo
Dietary Supplement · Other
Lead sponsor
Optimal Health Research
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 30, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

NCT01818986
View directory record Official record
Conditions
Metastatic Castrate-resistant Prostate Cancer, mCRPC
Interventions
Sipuleucel-T, Stereotactic Ablative Body Radiation
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 30, 2026, 10:15 PM EDT
Completed Phase 1Phase 2 Interventional

Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial

NCT06661902
View directory record Official record
Conditions
Prostate Cancer
Interventions
Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio), Lidocaine, Biopsy of Prostate, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 30, 2026, 10:15 PM EDT
Completed Phase 3 Interventional

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

NCT00003674
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Veno-occlusive Disease
Interventions
dalteparin, standard therapy
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
19
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 30, 2026, 10:15 PM EDT